Minerva Neurosciences (NERV) 10-Q2024 Q1 Quarterly report

Filed: 1 May 24, 7:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adult, affording, attention, concomitant, Connecticut, CRL, daily, deviation, East, electrocardiogram, emergent, enrolled, enrollment, FADP, grace, intentional, long, meaningful, Middle, mild, nonclinical, olanzapine, pharmacodynamic, pharmacokinetic, pharmacology, renewed, resolved, sequelae, smaller, symptomatic, therapy, voting, withdrew

Removed: abroad, accessibility, Addressing, adjusted, advance, aimed, alternate, Amendment, arbitrage, Asia, assessing, assuming, automatically, Baseline, began, beginning, Biden, biological, blind, blinded, boost, bring, bulk, called, capture, Center, Certificate, CGI, challenging, charged, civil, clarification, climate, CMS, combined, comparability, comparative, compare, compared, conducted, Congressional, considerable, consistently, constitute, controlling, cooperation, Cosmetic, country, dated, DB, deciding, Delaware, Department, detected, diminished, disfavor, division, double, earliest, Eastern, Economy, eligibility, employment, encourage, enforce, excluding, exploit, extended, fractional, free, frequently, Germany, globally, govern, governed, granting, group, harmonization, healthcare, HHS, high, higher, highlighted, hinder, hoc, HTA, identical, immigration, implausible, implementing, imply, importation, Impression, improve, improvement, incorporated, Incorporation, inflation, influence, Innovation, input, instability, instance, instituted, intrinsic, introduced, investigational, IRA, ITT, July, key, labor, legislation, legislative, lengthy, leverage, living, low, main, maintenance, mandatory, manifest, manufacturer, Marder, marginally, marketed, measuring, medical, Medicare, met, missed, Mitsubishi, mITT, modified, MTPC, multicenter, multinational, multiple, natural, newly, occur, occurred, official, OL, opened, opposed, outlining, outpace, par, parallel, passed, passing, payor, penalize, Pentagonal, placebo, planned, policy, political, population, Portugal, pose, post, predetermined, preferred, prescribed, prescribing, presently, President, Presidential, pressure, prevent, pricing, procedure, profitably, progressively, promote, promoting, promptly, proportionate, proportionately, proposal, PSM, PSP, psychiatric, quantitatively, randomized, reached, reassurance, reassured, receipt, recoup, recruited, reducing, reduction, reference, referencing, referred, reform, refund, reimburse, reimbursement, relationship, relaxation, released, relied, requested, reserved, restrict, restrictive, retroactively, reverse, Scale, score, Secretary, separately, setting, site, small, social, societal, Spain, specialty, split, stable, statistically, stockholder, Structured, submitting, subsidiary, succeed, superior, superiority, supported, supporting, Syndrome, Tanabe, tax, taxable, terrorism, thereof, tighter, transferred, traveling, treating, unacceptably, unadjusted, unavailable, unclear, unexpected, unfavorable, uniform, unrest, unsatisfactory, Utah, utilized, vocational, vulnerability, waiver, washout, week, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NERV similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

STATEMENT PURSUANT TO 18 U.S.C. § 1350

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Remy Luthringer, Executive Chairman and Chief Executive Officer (Principal Executive Officer) of Minerva Neurosciences, Inc. (the “Company”) and Frederick Ahlholm, Chief Financial Officer (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his knowledge:

(1)

The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

(2)

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


		/s/ Remy Luthringer, Ph.D.
Date: May 1, 2024		Remy Luthringer, Ph.D.
		Executive Chairman and Chief Executive Officer
		(Principal Executive Officer)

		/s/ Frederick Ahlholm
Date: May 1, 2024		Frederick Ahlholm
		Chief Financial Officer (Principal Financial Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Minerva Neurosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.